{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:04:32Z","timestamp":1793689472112,"version":"4.5.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,27]]},"abstract":"<jats:p>\n                    Anti-tumor necrosis factor treatments for inflammatory bowel disease face challenges like primary nonresponse and secondary loss of response, often due to antidrug antibodies that increase drug clearance. The Fc-gamma receptors type3A (FCGR3A) (rs396991) polymorphism affects infliximab pharmacokinetics and immunogenicity. This study investigates its influence on trough levels, anti-infliximab antibody development, and clinical outcomes in Iraqi ulcerative colitis (UC) patients. This single-center study involved patients on maintenance infliximab therapy who were enrolled. Serum infliximab trough levels and anti-infliximab antibodies (antibodies to infliximab) (free and total) were measured using enzyme-linked immunosorbent assay. Genotyping of the FCGR3A rs396991 polymorphism was performed via polymerase chain reaction amplification and Sanger sequencing. The partial Mayo score assessed disease activity. The significance level of statistics was\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.05. Among 43 patients, those with the CC genotype achieved target infliximab trough levels more frequently (55.6%) than AA (21.1%) or AC (0%) genotypes (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.005). Median infliximab levels were highest in CC carriers (3.41 \u00b5g\/mL,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.022). The AC genotype had a significantly higher prevalence of total anti-infliximab antibodies (53.3%) compared to CC (22.2%) and AA (10.5%) groups (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.02). Logistic regression confirmed the CC genotype positive association with therapeutic drug levels and lower antibody positivity, while the AC genotype correlated with increased immunogenicity. The FCGR3A rs396991 CC genotype is significantly associated with improved infliximab pharmacokinetics and reduced immunogenicity in UC patients. These findings highlight the potential of FCGR3A genotyping to guide personalized therapeutic strategies and optimize clinical outcomes in UC.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000046119","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T01:00:59Z","timestamp":1772240459000},"page":"e46119","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Fc-gamma receptors type3A (rs396991) genotyping for predicting infliximab efficacy and immunogenicity in ulcerative colitis: An observational study of Iraqi cohort"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9154-7823","authenticated-orcid":false,"given":"Ahmad K.","family":"Al-Jalehawi","sequence":"first","affiliation":[{"name":"Clinical Pharmacy Department, College of Pharmacy, University of Baghdad, Baghdad, Iraq"},{"name":"Clinical Pharmacy Department, College of Pharmacy, University of Alkafeel, Najaf, Iraq."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7073-9976","authenticated-orcid":false,"given":"Samer Imad","family":"Mohammed","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Department, College of Pharmacy, University of Baghdad, Baghdad, Iraq"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260413","doi-asserted-by":"crossref","first-page":"335","DOI":"10.61873\/SEZR6390","article-title":"Clinical use of tumor necrosis factor-alpha inhibitors in Iraq: a review of their documented efficacy, safety, and associated genetics.","volume":"38","author":"Al-Jalehawi","year":"2024","journal-title":"Rev Clin Pharmacol Pharmacokinetics Int Edition"},{"key":"R2-20260413","first-page":"78","article-title":"Infliximab therapy in Iraqi patients with moderate to severe psoriasis.","volume":"05","author":"Al-Hamamy","year":"2015","journal-title":"J Cosmetics Dermatol Sci Appl"},{"key":"R3-20260413","first-page":"46","article-title":"Effectiveness of infliximab and adalimumab in Iraqi patients with ulcerative colitis \u2013 real-world data.","volume":"10","author":"Mohammed","year":"2020","journal-title":"J Adv Pharmacy Educ Res"},{"key":"R4-20260413","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.15666\/aeer\/1804_55055525","article-title":"Primary non-response in inflammatory bowel disease, definition, potential causes, therapeutic drug monitoring and microbiota \u2013 a review.","volume":"18","author":"Alatawi","year":"2020","journal-title":"Appl Ecol Environm Res"},{"key":"R5-20260413","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1080\/17425255.2017.1377180","article-title":"Primary and secondary nonresponse to infliximab: mechanisms and countermeasures.","volume":"13","author":"Wong","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R6-20260413","doi-asserted-by":"crossref","first-page":"241","DOI":"10.32007\/jfacmedbagdad.573372","article-title":"Development of anti-bodies against infliximab in Iraqi patients with rheumatoid arthritis.","volume":"57","author":"Al-Karkhi","year":"2015","journal-title":"J Faculty Med Baghdad"},{"key":"R7-20260413","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/clpt.2011.328","article-title":"Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms.","volume":"91","author":"Ord\u00e1s","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"R8-20260413","doi-asserted-by":"crossref","first-page":"239","DOI":"10.54133\/ajms.v6i1.606","article-title":"Correlation between therapeutic drug monitoring of infliximab serum trough levels and other biomarkers in Iraqi patients with Crohn\u2019s disease.","volume":"6","author":"Saleh","year":"2024","journal-title":"Al-Rafidain J Med Sci"},{"key":"R9-20260413","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1172\/JCI106279","article-title":"Metabolic properties of IgG subclasses in man.","volume":"49","author":"Morell","year":"1970","journal-title":"J Clin Invest"},{"key":"R10-20260413","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3390\/jpm11060573","article-title":"Influence of the fcgr2a rs1801274 and fcgr3a rs396991 polymorphisms on response to abatacept in patients with rheumatoid arthritis.","volume":"11","author":"M\u00e1rquez Pete","year":"2021","journal-title":"J Pers Med"},{"key":"R11-20260413","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00251-013-0679-8","article-title":"FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn\u2019s disease through affecting the ADCC activity.","volume":"65","author":"Moroi","year":"2013","journal-title":"Immunogenetics"},{"key":"R12-20260413","doi-asserted-by":"crossref","first-page":"1096816","DOI":"10.3389\/fphar.2023.1096816","article-title":"Association between genetic variants and development of antibodies to infliximab: a cross-sectional study in Chinese patients with Crohn\u2019s disease.","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Pharmacol"},{"key":"R13-20260413","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1111\/cts.13075","article-title":"Pharmacogenetic variants of infliximab response in young patients with inflammatory bowel disease.","volume":"14","author":"Curci","year":"2021","journal-title":"Clin Transl Sci"},{"key":"R14-20260413","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/apt.13736","article-title":"Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases.","volume":"44","author":"Bek","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R15-20260413","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7150\/ijms.22812","article-title":"A FCGR3A polymorphism predicts anti-drug antibodies in chronic inflammatory bowel disease patients treated with anti-TNF.","volume":"15","author":"Romero-Cara","year":"2018","journal-title":"Int J Med Sci"},{"key":"R16-20260413","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2036.2004.01871.x","article-title":"Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn\u2019s disease.","volume":"19","author":"Louis","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"R17-20260413","doi-asserted-by":"crossref","first-page":"110","DOI":"10.37897\/RJR.2023.3.3","article-title":"Association between genetic polymorphism in tumor necrosis factor-alpha gene and adverse effects of etanercept in rheumatoid arthritis patients.","volume":"32","author":"Mohammed","year":"2023","journal-title":"Romanian Jo Rheumatol"},{"key":"R18-20260413","doi-asserted-by":"crossref","first-page":"24","DOI":"10.54133\/ajms.v4i.100","article-title":"The association of genetic polymorphisms in tumor necrosis factor-alpha and interleukins with disease severity or response to biological therapy in Iraqi rheumatoid arthritis patients: a narrative review.","volume":"4","author":"Mohammed","year":"2023","journal-title":"Al-Rafidain J Med Sci"},{"key":"R19-20260413","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.21608\/ejhm.2023.291469","article-title":"The impact of rs767455 and rs1061622 polymorphisms on treatment outcomes in Iraqi ankylosing spondylitis patients taking etanercept.","volume":"90","author":"Khudhur","year":"2023","journal-title":"Egypt J Hosp Med"},{"key":"R20-20260413","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1172\/JCI119616","article-title":"A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease.","volume":"100","author":"Wu","year":"1997","journal-title":"J Clin Invest"},{"key":"R21-20260413","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1136\/ard.2007.086892","article-title":"A polymorphism in the gene encoding the Fcgamma IIIA receptor is a possible genetic marker to predict the primary response to infliximab in Japanese patients with rheumatoid arthritis.","volume":"67","author":"Tsukahara","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R22-20260413","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/01.fpc.0000230421.12844.fd","article-title":"Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn\u2019s disease: a subanalysis of the ACCENT I study.","volume":"16","author":"Louis","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"R23-20260413","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/gut.2009.183095","article-title":"Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis.","volume":"59","author":"Seow","year":"2010","journal-title":"Gut"},{"key":"R24-20260413","first-page":"40","article-title":"Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis.","volume":"2012","author":"Nanda","journal-title":"Am J Gastroenterolol"},{"key":"R25-20260413","first-page":"674","article-title":"Infliximab trough levels among patients with inflammatory bowel disease in correlation with infliximab treatment escalation: a cross-sectional study from a Greek tertiary center.","volume":"37","author":"Orfanidou","year":"2024","journal-title":"Ann Gastroenterol"},{"key":"R26-20260413","doi-asserted-by":"crossref","first-page":"18240","DOI":"10.1038\/s41598-025-02463-4","article-title":"Association of the TNFRSF1B-rs1061622 variant with nonresponse to infliximab in ulcerative colitis.","volume":"15","author":"Tessier","year":"2025","journal-title":"Sci Rep"},{"key":"R27-20260413","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s40262-014-0225-3","article-title":"Assessment of the influence of inflammation and FCGR3A genotype on infliximab pharmacokinetics and time to relapse in patients with Crohn\u2019s disease.","volume":"54","author":"Termant","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"R28-20260413","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3390\/ijms26041760","article-title":"Pharmacogenetics in response to biological agents in inflammatory bowel disease: a systematic review.","volume":"26","author":"Ballesta-L\u00f3pez","year":"2025","journal-title":"Int J Mol Sci"},{"key":"R29-20260413","doi-asserted-by":"crossref","first-page":"100","DOI":"10.31351\/vol31issSuppl.pp100-110","article-title":"Cost-effectiveness analysis of reference infliximab (Remicade) compared to its biosimilar (Remsima) in Iraqi patients with rheumatoid arthritis.","volume":"31","author":"Fadhil","year":"2022","journal-title":"Iraqi J Pharm Sci"},{"key":"R30-20260413","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.cgh.2012.10.020","article-title":"Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease.","volume":"11","author":"Ben-Horin","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R31-20260413","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/jpn3.12074","article-title":"Anti-infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel disease.","volume":"78","author":"Zitomersky","year":"2023","journal-title":"J Pediatr Gastroenterol Nutr"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000046119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:17:23Z","timestamp":1785784643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000046119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046119","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"2025-08-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}